Unraveling the interplay of hemodynamic and biomechanical determinants in glaucoma pathophysiology

Active Grant Awarded

Award ID
R01EY037891
Recipient
Awarding agency
Obligated
$496,541

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date 5% complete
Place of performance
West Virginia, USA

Award details come from USAspending.gov.

About this award

Department of Health and Human Services National Institutes of Health National Eye Institute awarded West Virginia University Research Corporation $496,541 on August 21, 2026, under Assistance Listing 93.859, Biomedical Research and Research Training, for grant R01EY037891, "Unraveling the Interplay of Hemodynamic and Biomechanical Determinants in Glaucoma Pathophysiology." The recipient will integrate super-resolution ultrasound localization microscopy with ultrasound elastography strain tracking in a small animal model to investigate interactions between systemic and ocular hemodynamics and peripapillary sclera and optic nerve head biomechanics. The investigators hypothesize that hemodynamic instability and elevated intraocular pressure drive peripapillary sclera remodeling that increases axon-damaging mechanical insults, and they propose testing whether anti-fibrotic and vasodilatory pharmaceuticals can target that remodeling. Obligated funding is $496,541, with ultimate completion on July 31, 2031, and place of performance in West Virginia, USA. The Ohio State University Office of Sponsored Programs holds sub-award R01EY037891-SUB00003315, dated November 10, 2026, under the same project title.

Description

Abstract
Glaucoma, the leading cause of irreversible blindness worldwide, is an optic neuropathy characterized by the progressive loss of retinal ganglion cells (RGCS) and structural changes to the optic nerve head (ONH) connective tissues. While current treatments focus on reducing intraocular pressure (IOP) to alleviate mechanical stress on the ONH, many patients continue to experience disease progression despite successful IOP reduction, underscoring the need for adjunct neuroprotective strategies. Targeting the mechanisms underlying pathologic remodeling of the peripapillary sclera (PPS) and ocular vascular dysregulation would offer a novel therapeutic approach, particularly for patients less responsive to IOP-lowering therapies. However, a deeper understanding of the interplay between ocular perfusion and biomechanics is crucial for developing treatments to enhance the ONH's resilience to glaucomatous stressors. We have pioneered a multi-parametric ultrasound imaging approach capable of assessing both volumetric ocular perfusion and tissue strain at depths most relevant to glaucoma pathophysiology, which cannot currently be achieved with optical methods. The objective of this proposal is to integrate super-resolution ultrasound localization microscopy (ULM) with ultrasound elastography strain tracking in a small animal model to investigate the complex interactions between systemic and ocular hemodynamics and PPS/ONH biomechanics. We hypothesize that hemodynamic instability and elevated IOP lead to remodeling of the PPS that increases axon-damaging mechanical insults within the ONH. Furthermore, we propose that this adverse remodeling can be targeted with pharmaceuticals that promote anti-fibrotic and vasodilatory mechanisms in the eye. The goals of this proposal are to use our innovative ultrasound methods to: 1) determine whether chronically reduced BP in a RAT model results in decreased ocular perfusion, leading to PPS stiffening and RGC axonal damage, and 2) evaluate whether treatments designed to improve ocular perfusion and mitigate PPS remodeling provide neuroprotection in chronic ocular hypertension RAT models. By leveraging novel ocular imaging, we aim to expand the scope of glaucoma treatment by studying how established glaucoma risk factors affect the disease's vascular and biomechanical mechanisms-two prevailing paradigms in glaucoma pathophysiology, which have historically been studied in isolation. We will explore whether modifying the mechanovascular environment of the ONH with clinically translatable therapeutics can protect RGCS from glaucoma damage, potentially offering vital non-IOP lowering treatment options to glaucoma sufferers.

Transactions

Action Obligated Date
Amendment $350,000
Original award $146,541

Subawards

Subrecipient Amount Awarded
The Ohio State University Unraveling the Interplay of Hemodynamic and Biomechanical Determinants in Glaucoma Pathophysiology $123,306

Quick answers

Who received award R01EY037891?

R01EY037891 was awarded to West Virginia University Research Corporation by National Eye Institute (National Institutes of Health) on August 21, 2026.

How much is award R01EY037891 worth?

$496,541 has been obligated on R01EY037891.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award